Journal articles: 'Drugs design'

1

Bugg, Charles E., William M. Carson, and John A. Montgomery. "Drugs by Design." Scientific American 269, no. 6 (December 1993): 92–98. http://dx.doi.org/10.1038/scientificamerican1293-92.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

BORMAN, STU. "DRUGS BY DESIGN." Chemical & Engineering News Archive 83, no. 48 (November 28, 2005): 28–30. http://dx.doi.org/10.1021/cen-v083n048.p028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Krasnopolsky, Yu М. ""QUALITY BY DESIGN" IN LIPOSOMAL DRUGS CREATION." Biotechnologia Acta 13, no. 6 (December 2020): 5–12. http://dx.doi.org/10.15407/biotech13.06.005.

Full text

Abstract:

Nanobiotechnological preparations creation is one of the promising areas of modern pharmacy, since it allows creating products of a qualitatively new level. The procedure development, based on an understanding of the product characteristics and the technological process, confirmed by reliable scientific data. The article is devoted to the pharmaceutical development of liposomal drugs. On the basis of our own experience in the development of liposomal medicinal forms, as well as on the basis of literature data, the main components in their composition were detected and these components impact on the quality indicators of liposomes were studied. Individual lipids function in nanoparticle membrane and their interaction, which determines the stability both in the technological process and upon storage of the product, were considered. The advantages and disadvantages of cholesterol incorporation into liposomes with hydrophilic and hydrophobic active pharmaceutical ingredients were described. Cryoprotectors and buffer systems role in ensuring nanopreparation stability is discussed.

APA, Harvard, Vancouver, ISO, and other styles

4

Snyder, Solomon H. "Pharmacology: Virtuoso design of drugs." Nature 323, no. 6086 (September 1986): 292–93. http://dx.doi.org/10.1038/323292a0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Williams, Bryan R. G. "Design of anti-AIDS drugs." Virus Research 19, no. 1 (March 1991): 130. http://dx.doi.org/10.1016/0168-1702(91)90102-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

YOKOYAMA, MASAYUKI. "Molecular design of missile drugs." Kagaku To Seibutsu 26, no. 3 (1988): 199–202. http://dx.doi.org/10.1271/kagakutoseibutsu1962.26.199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ferriz, J. M., and J. Vinsova. "Prodrug Design of Phenolic Drugs." Current Pharmaceutical Design 16, no. 18 (June 1, 2010): 2033–52. http://dx.doi.org/10.2174/138161210791293042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal." Pharmaceutical Journal of Indonesia 6, no. 1 (December 1, 2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Full text

Abstract:

The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative study with a cross sectional design. Data were taken from 100 medical records of patients who had diagnosed with top five musculoskeletal diseases. Data were analyzed descriptively for sex, ages, number of drugs, type of drugs, and potential drug interactions. Bivariate correlation with chi-square were conducted to find statistically significancy potential drug interactions with each variable consist of sex, ages, type of drugs and it’s diagnose. The result shows that the musculoskeletal patients were 44% male, 56% female. Most musculoskeletal patients were aged 18-65 years (78%). Patients who received drugs <5 were 68% and ≥ 5 were 32%. 54% of patients were taking the diclofenac and only 5% of patients were taking the two NSAIDs combination, diclofenac and ibuprofen. There was no significant correlation (p > 0,05) between potential drug interactions with age, sex, type of NSAID, and type of musculosceletal diseases.

APA, Harvard, Vancouver, ISO, and other styles

9

Carlson, Robert. "Supercomputers help design drugs super fast." Inpharma Weekly &NA;, no. 1155 (September 1998): 9–10. http://dx.doi.org/10.2165/00128413-199811550-00019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Korcsmáros, Tamás, Máté S. Szalay, Csaba Böde, István A. Kovács, and Péter Csermely. "How to design multi-target drugs." Expert Opinion on Drug Discovery 2, no. 6 (June 2007): 799–808. http://dx.doi.org/10.1517/17460441.2.6.799.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Immadisetty, Kalyan, Laura M. Geffert, Christopher K. Surratt, and Jeffry D. Madura. "New design strategies for antidepressant drugs." Expert Opinion on Drug Discovery 8, no. 11 (August 31, 2013): 1399–414. http://dx.doi.org/10.1517/17460441.2013.830102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Malik, Ravinder, and Ipsita Roy. "Design and development of antisense drugs." Expert Opinion on Drug Discovery 3, no. 10 (September 28, 2008): 1189–207. http://dx.doi.org/10.1517/17460441.3.10.1189.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lipkin, R. "New 'Design Rules' Yield Novel Drugs." Science News 147, no. 24 (June 17, 1995): 374. http://dx.doi.org/10.2307/3978896.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Nussinov, Ruth, and Chung-Jung Tsai. "The Design of Covalent Allosteric Drugs." Annual Review of Pharmacology and Toxicology 55, no. 1 (January 6, 2015): 249–67. http://dx.doi.org/10.1146/annurev-pharmtox-010814-124401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Navia, M. A. "Rational design of new immunosuppressive drugs." Transplantation Proceedings 31, no. 1-2 (February 1999): 1097–98. http://dx.doi.org/10.1016/s0041-1345(98)01917-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

HOPKINS, A., J. MASON, and J. OVERINGTON. "Can we rationally design promiscuous drugs?" Current Opinion in Structural Biology 16, no. 1 (February 2006): 127–36. http://dx.doi.org/10.1016/j.sbi.2006.01.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Shugar, David. "Design of enzyme inhibitors as drugs." FEBS Letters 258, no. 2 (December 4, 1989): 355. http://dx.doi.org/10.1016/0014-5793(89)81692-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Tomlinson, E. "Design of site-specific protein drugs." Science of The Total Environment 109-110 (December 1991): 9–16. http://dx.doi.org/10.1016/0048-9697(91)90166-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Whiteley, John M. "Design of enzyme inhibitors as drugs." Trends in Biochemical Sciences 14, no. 10 (October 1989): 427–28. http://dx.doi.org/10.1016/0968-0004(89)90305-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Taylor, Buck. "Giveaway Drugs: Good Intentions, Bad Design." Health Affairs 23, no. 1 (January 2004): 213–17. http://dx.doi.org/10.1377/hlthaff.23.1.213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Liang, Jun, Min Huang, Wei Duan, Xue-Qing Yu, and Shufeng Zhou. "Design of New Oxazaphosphorine Anticancer Drugs." Current Pharmaceutical Design 13, no. 9 (March 1, 2007): 963–78. http://dx.doi.org/10.2174/138161207780414296.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Callingham, Brian. "Design of enzyme inhibitors as drugs." Trends in Pharmacological Sciences 10, no. 10 (October 1989): 424–25. http://dx.doi.org/10.1016/0165-6147(89)90194-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Crowley, Patrick J., and Luigi G. Martini. "Formulation design: new drugs from old." Drug Discovery Today: Therapeutic Strategies 1, no. 4 (December 2004): 537–42. http://dx.doi.org/10.1016/j.ddstr.2004.11.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

NAVIA, M., and P. CHATURVEDI. "Design principles for orally bioavailable drugs." Drug Discovery Today 1, no. 5 (May 1996): 179–89. http://dx.doi.org/10.1016/1359-6446(96)10020-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Müller, Klaus, and Hans-Joachim Böhm. "Facilitating the Design of Fluorinated Drugs." Chemistry & Biology 16, no. 11 (November 2009): 1130–31. http://dx.doi.org/10.1016/j.chembiol.2009.11.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wold, Svante. "Multidimensional Pharmacochemistry. Design of Safer Drugs." Journal of Pharmaceutical Sciences 74, no. 11 (November 1985): 1247. http://dx.doi.org/10.1002/jps.2600741124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Cereghino, James J. "Clinical trial design for antiepileptic drugs." Annals of Neurology 32, no. 3 (September 1992): 393–94. http://dx.doi.org/10.1002/ana.410320314.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Beydoun, Ahmad. "Sequential Design Studies for Antiepileptic Drugs." Epilepsy & Behavior 3, no. 2 (April 2002): 107–8. http://dx.doi.org/10.1006/ebeh.2002.0338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Siddeswari T, Panneerselvam P, Vijayamma G, Nithya Kalyani K, Jeslin D, and Suryasree Y. "Design and validation of the Gingkolide estimation using RP-HPLC analytical tool." International Research Journal of Pharmaceutical and Applied Sciences 11, no. 1 (February 26, 2021): 1–5. http://dx.doi.org/10.26452/irjpas.v11i1.1394.

Full text

Abstract:

Gingkolide is an antiseizure medicine used as an adjuvant of partial seizures and GAD to relieve neuropathic pain. It binds to the very high affinity alpha delta site in the CNS. Although the drug's mechanism remains unclear, in genetically engineered mice and other anticonvulsive models, findings showed that it binds to alpha receptors. A rapid rise in the number of drugs added to each class of drugs has been noted. Whether in a single or multi-drug delivery form, these medications are developed into newer formulations. These newest formulations put on the market need a new investigation to estimate the medication in the formulations. In the scientific literature, the current analytical procedures for such drugs are available, but not all approaches are stable and economical to use. Few other techniques are often time-consuming. The goal of this work was to develop an RP-HPLC analytical tool for Gingkolide estimation. The drug's RP-PLC study meets the drug's optimum integrity, suitability, regeneration. The drug's LOQ and LOD were reached with elevated sensitivity. Overall, the results show that the recommended analytical approach in the formulation should be used to evaluate the drug. For regular study of the medication in its dosage form, this approach may be recommended.

APA, Harvard, Vancouver, ISO, and other styles

30

Ning, Lin, Bifang He, Peng Zhou, Ratmir Derda, and Jian Huang. "Molecular Design of Peptide-Fc Fusion Drugs." Current Drug Metabolism 20, no. 3 (May 22, 2019): 203–8. http://dx.doi.org/10.2174/1389200219666180821095355.

Full text

Abstract:

Background:Peptide-Fc fusion drugs, also known as peptibodies, are a category of biological therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest. However, to develop such kind of drugs is laborious and expensive. Rational design is urgently needed.Methods:We summarized the key steps in peptide-Fc fusion technology and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs. We also raised open questions about the computer-aided molecular design of peptide-Fc.Results:The design of peptibody consists of four steps. First, identify peptide leads from native ligands, biopanning, and computational design or prediction. Second, select the proper Fc region from different classes or subclasses of immunoglobulin. Third, fuse the peptide leads and Fc together properly. At last, evaluate the immunogenicity of the constructs. At each step, there are quite a few useful resources and computational tools.Conclusion:Reviewing the molecular design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.

APA, Harvard, Vancouver, ISO, and other styles

31

Buchwald, Peter. "Computer-aided retrometabolic drug design: soft drugs." Expert Opinion on Drug Discovery 2, no. 7 (July 2007): 923–33. http://dx.doi.org/10.1517/17460441.2.7.923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

De Clercq, Erik. "Strategies in the design of antiviral drugs." Nature Reviews Drug Discovery 1, no. 1 (January 2002): 13–25. http://dx.doi.org/10.1038/nrd703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Fricker, Simon Paul. "Metal based drugs: from serendipity to design." Dalton Transactions, no. 43 (2007): 4903. http://dx.doi.org/10.1039/b705551j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Pinheiro, M. P., J. R. da Rocha, J. Cheleski, H. J. Wiggers, C. A. Montanari, and M. C. Nonato. "Structure-based design of anti-trypanosomal drugs." Acta Crystallographica Section A Foundations of Crystallography 67, a1 (August 22, 2011): C294. http://dx.doi.org/10.1107/s0108767311092646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Walsh, John S., and Gerald T. Miwa. "Bioactivation of Drugs: Risk and Drug Design." Annual Review of Pharmacology and Toxicology 51, no. 1 (February 10, 2011): 145–67. http://dx.doi.org/10.1146/annurev-pharmtox-010510-100514.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Deng, Xiaotie, Guojun Li, Zimao Li, Bin Ma, and Lusheng Wang. "Genetic Design of Drugs Without Side-Effects." SIAM Journal on Computing 32, no. 4 (January 2003): 1073–90. http://dx.doi.org/10.1137/s0097539701397825.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Jackson, Graham E., Lomkhosi Mkhonta-Gama, Alex Voyé, and Mark Kelly. "Design of copper-based anti-inflammatory drugs." Journal of Inorganic Biochemistry 79, no. 1-4 (April 2000): 147–52. http://dx.doi.org/10.1016/s0162-0134(99)00171-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Moutevelis-Minakakis, P., M. Gianni, H. Stougiannou, P. Zoumpoulakis, A. Zoga, A. D. Vlahakos, E. Iliodromitis, and T. Mavromoustakos. "Design and synthesis of novel antihypertensive drugs." Bioorganic & Medicinal Chemistry Letters 13, no. 10 (May 2003): 1737–40. http://dx.doi.org/10.1016/s0960-894x(03)00251-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Anand, CV. "The design of drugs to macromolecular targets." Biochemical Education 22, no. 1 (January 1994): 39. http://dx.doi.org/10.1016/0307-4412(94)90168-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Larrick, James W., and Yuqiang Wang. "Pharmaceutical design II: Nucleic acid binding drugs." Gene 149, no. 1 (November 1994): 1–2. http://dx.doi.org/10.1016/0378-1119(94)90404-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Bradbury, Jane. "Rational design of peptide drugs: avoiding aggregation." Drug Discovery Today 10, no. 18 (September 2005): 1208–9. http://dx.doi.org/10.1016/s1359-6446(05)03603-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

BALAJI, V. N., J. SCOTT DIXON, D. H. SMITH, R. VENKATARAGHAVAN, and K. C. MURDOCK. "Design of Anticancer Drugs Using Modeling Techniques." Annals of the New York Academy of Sciences 439, no. 1 Macromolecula (March 1985): 140–61. http://dx.doi.org/10.1111/j.1749-6632.1985.tb25794.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Cody, Vivian. "The design of drugs to macromolecular targets." Journal of Molecular Graphics 11, no. 3 (September 1993): 214. http://dx.doi.org/10.1016/0263-7855(93)80076-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Saunders, John. "The design of drugs to macromolecular targets." Trends in Pharmacological Sciences 14, no. 4 (April 1993): 135. http://dx.doi.org/10.1016/0165-6147(93)90088-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Wermuth, Camille G. "Similarity in drugs: reflections on analogue design." Drug Discovery Today 11, no. 7-8 (April 2006): 348–54. http://dx.doi.org/10.1016/j.drudis.2006.02.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Plescia, Jessica, and Nicolas Moitessier. "Design and discovery of boronic acid drugs." European Journal of Medicinal Chemistry 195 (June 2020): 112270. http://dx.doi.org/10.1016/j.ejmech.2020.112270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Singh, Parvesh, and Vipan Kumar. "Special Issue “Hybrid Drugs: Design and Applications”." Pharmaceuticals 16, no. 10 (September 26, 2023): 1358. http://dx.doi.org/10.3390/ph16101358.

Full text

Abstract:

The widely held belief in the potential superiority of agents capable of modulating multiple biological targets has led to the adoption of molecular hybridization as an effective technique in the realm of drug discovery and development [...]

APA, Harvard, Vancouver, ISO, and other styles

48

Tee, Wei-Ven, and Igor N. Berezovsky. "Allosteric drugs: New principles and design approaches." Current Opinion in Structural Biology 84 (February 2024): 102758. http://dx.doi.org/10.1016/j.sbi.2023.102758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Gasco, Alberto, Donatella Boschi, Konstantin Chegaev, Clara Cena, Antonella Di Stilo, Roberta Fruttero, Loretta Lazzarato, Barbara Rolando, and Paolo Tosco. "Multitarget drugs: Focus on the NO-donor hybrid drugs." Pure and Applied Chemistry 80, no. 8 (January 1, 2008): 1693–701. http://dx.doi.org/10.1351/pac200880081693.

Full text

Abstract:

The article addresses the design of multitarget drugs, namely, compounds capable of interacting with more than one target simultaneously. These agents could be useful tools in the therapy of complex diseases such as cardiovascular and inflammatory diseases. An interesting case of multitarget compounds are nitric oxide (NO)-donor hybrids, structures which combine the physiological properties of NO with those of a lead drug. In particular, the authors discuss the symbiotic approach used to design NO-donor nonsteroidal anti-inflammatory drugs (NO-NSAIDs) and NO-donor antioxidants. The former could be useful agents in the treatment of anti-inflammatory diseases being devoid of gastro- and cardiotoxicity, the latter could be a valid approach to the treatment of many cardiovascular diseases.

APA, Harvard, Vancouver, ISO, and other styles

50

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (September 16, 2019): 134. http://dx.doi.org/10.3390/ph12030134.

Full text

Abstract:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Drugs design'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles